In this abstract presentation, Dr. Paul G. Richardson discusses the results of a mutlicenter Phase 2 trial on the use of ibrutinib in combination with low-dose dexamethasone in patients with relapsed or relapsed and refractory multiple meyloma.
A continuing education program is offered as a supplement to this webcast at the following location:
http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP
© 2015 Imedex, LLC.
Advertisement